Mesna - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

uromitexan mesna 600mg tablet blister pack

baxter healthcare pty ltd - mesna, quantity: 600 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; maize starch; povidone; magnesium stearate; hypromellose; macrogol 6000; titanium dioxide; simethicone - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects section of the cyclophosphamide and ifosfamide product information)

Australia - English - Department of Health (Therapeutic Goods Administration)

uromitexan mesna 400mg tablet blister pack

baxter healthcare pty ltd - mesna, quantity: 400 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; maize starch; povidone; magnesium stearate; hypromellose; macrogol 6000; titanium dioxide; simethicone - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects section of the cyclophosphamide and ifosfamide product information)

United States - English - NLM (National Library of Medicine)

mesna injection, solution

hikma farmaceutica - mesna (unii: nr7o1405q9) (2-mercaptoethanesulfonic acid - unii:vhd28s0h7f) -

Ireland - English - HPRA (Health Products Regulatory Authority)

uromitexan tablets 400mg

baxter holding b.v. - mesna - film-coated tablet - 400 milligram(s) - detoxifying agents for antineoplastic treatment; mesna

United States - English - NLM (National Library of Medicine)

mesnex- mesna injection, solution

baxter healthcare corporation - mesna (unii: nr7o1405q9) (2-mercaptoethanesulfonic acid - unii:vhd28s0h7f) - mesnex is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. limitation of use: mesnex is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. mesnex is contraindicated in patients known to be hypersensitive to mesnex or to any of the excipients [ see warnings and precautions (5.1)]. risk summary there are no studies of mesnex in pregnant women. reproduction studies performed in rats and rabbits at oral doses approximately 10 times the maximum recommended total daily intravenous-oral-oral human dose on a body surface area basis (1000 mg/kg in rabbits and 2000 mg/kg in rats) revealed no evidence of harm to the fetus due to mesna. the incidence of malformations in human pregnancies has not been established for mesnex. all pregnancies, regardless of drug exposure, have a background rate of 2 to 4% for major malformations and 15 to 20% for pregnancy loss. because animal reproductive studies are not al